Showing 1681-1690 of 3315 results for "".
- Hovione Completes Phase 2 Clinical Trial of First Minocycline Ophthalmic for Dry Eye Disease Associated With Inflamed MGDhttps://modernod.com/news/hovione-completes-phase-2-clinical-trial-of-first-minocycline-ophthalmic-showing-promise-in-dry-eye-disease-associated-with-inflamed-mgd/2478986/Hovione announced at the Ophthalmology Innovation Summit (OIS) Dry Eye Showcase the successful completion of its phase 2 clinical trial in 270 patients with dry eye caused by Meibomian Gland Dysfunction (MGD). The well controlled and representative study was conducted across 26 clinical sites in
- Holland Foundation for Sight Restoration Launched to Provide Life Changing Eye Surgerieshttps://modernod.com/news/holland-foundation-for-sight-restoration-launched-to-provide-life-changing-eye-surgeries/2479402/Edward Holland, MD, a pioneering ophthalmologist in the treatment of Severe Ocular Surface Disease, today announced the launch of the Holland Foundation for Site Restoration with a goal of establishing Centers of Excellence (COEs) throughout the country that would specialize in site restoration p
- Ocuphire Initiates Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Presbyopiahttps://modernod.com/news/ocuphire-initiates-enrollment-in-vega-1-phase-2-trial-investigating-nyxol-in-presbyopia/2478887/Ocuphire Pharma announced that it has enrolled the first patients in a phase 2 proof of concept trial, titled VEGA-1, to evaluate a combination kit of Nyxol and low-dose pilocarpine in presbyopia. Over 12 sites representing a majority of the planned clinical sites are activated and recruiting pat
- Ribomic Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study) in Subjects with Wet AMDhttps://modernod.com/news/ribomic-announces-first-injection-in-the-phase-2-clinical-trial-of-rbm-007-tofu-study-in-subjects-with-wet-amd/2477304/Ribomic announced that first patient has received injection in the phase 2 trial of RBM-007 for the treatment of wet age-related macular degeneration (AMD) in the United States. The first site started enrollment at the end of December 2019 and five sites are now active across the United States.</
- Katena Products Announces Launch of the New Katena.comhttps://modernod.com/news/katena-products-announces-launch-of-the-new-katena-com/2479878/Katena Products has announced the launch of the new katena.com, an interactive and engaging ecommerce and education portal. The new site enables existing and prospective customers to review the complete assortment of Katena products and immediately order online. The new site integrates all
- SiteOne Therapeutics Receives NIH Grant to Support the Development of Novel Therapeutics to Treat Ocular Painhttps://modernod.com/news/siteone-therapeutics-receives-nih-grant-to-support-the-development-of-novel-therapeutics-to-treat-ocular-pain/2479849/SiteOne Therapeutics announced that the company has been awarded a $1.4 million, 2-year, phase 2 SBIR grant from the National Eye Institute (NEI), a member of the US National Institutes of Health (NIH). The award will be used to initiate IND-enabling studies for Site
- Oxford Finance Provides $125 Million Credit Facility to Kala Pharmaceuticalshttps://modernod.com/news/oxford-finance-provides-125-million-credit-facility-to-kala-pharmaceuticals/2479229/Oxford Finance has announced the closing of a $125 million senior secured term loan with Kala Pharmaceuticals. Proceeds from the transaction will be used to refinance existing indebtedness and provide additional growth capital for the company’s marketing of its two approved ophthalmic products.</
- Oertli Opens New Lean Factory Building in Berneck, Eastern Switzerlandhttps://modernod.com/news/oertli-opens-new-lean-factory-building-in-berneck-eastern-switzerland/2481922/Oertli Instrumente recently celebrated the opening of its new Lean Factory building at its main site in Berneck, Eastern Switzerland. The new Lean Factory covers 11,000 m2 and has the goal of increasing production efficiency and volumes in order to achieve the set growth targets. With a
- FDA Approves New Paragon Contact Lens Manufacturing Facility in Phoenixhttps://modernod.com/news/fda-approves-new-paragon-contact-lens-manufacturing-facility-in-phoenix/2476817/The FDA has approved Paragon Vision Science’s newly-constructed contact lens manufacturing site in suburban Phoenix, paving the way for the company’s ongoing domestic and global expansion. The Gilbert, Ariziona facility will produce advanced ortho-k products such as Paragon CRT for use in
- LensGen Will Present Early Results Of International “Grail” Study At ASCRShttps://modernod.com/news/lensgen-will-present-early-results-of-international-grail-study-at-ascrs/2476515/LensGen will share results from its “Grail” study at the ASCRS annual meeting in San Diego, May 3-7. The results will include the latest available data on patients who have been treated at two international sites.